posted on 2003-08-12, 00:00authored byJ. Scott Sawyer, Bryan D. Anderson, Douglas W. Beight, Robert M. Campbell, Michael L. Jones, David K. Herron, John W. Lampe, Jefferson R. McCowan, William T. McMillen, Nicholas Mort, Stephen Parsons, Edward C. R. Smith, Michal Vieth, Leonard C. Weir, Lei Yan, Faming Zhang, Jonathan M. Yingling
Pyrazole-based inhibitors of the transforming growth
factor-β type I receptor kinase domain (TβR-I) are described.
Examination of the SAR in both enzyme- and cell-based in
vitro assays resulted in the emergence of two subseries
featuring differing selectivity versus p38 MAP kinase. A
common binding mode at the active site has been established
by successful cocrystallization and X-ray analysis of potent
inhibitors with the TβR-I receptor kinase domain.